These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

885 related items for PubMed ID: 22517769

  • 1. Effect of a glucagon-like peptide 1 analog, ROSE-010, on GI motor functions in female patients with constipation-predominant irritable bowel syndrome.
    Camilleri M, Vazquez-Roque M, Iturrino J, Boldingh A, Burton D, McKinzie S, Wong BS, Rao AS, Kenny E, Månsson M, Zinsmeister AR.
    Am J Physiol Gastrointest Liver Physiol; 2012 Jul; 303(1):G120-8. PubMed ID: 22517769
    [Abstract] [Full Text] [Related]

  • 2. Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome.
    Andresen V, Camilleri M, Busciglio IA, Grudell A, Burton D, McKinzie S, Foxx-Orenstein A, Kurtz CB, Sharma V, Johnston JM, Currie MG, Zinsmeister AR.
    Gastroenterology; 2007 Sep; 133(3):761-8. PubMed ID: 17854590
    [Abstract] [Full Text] [Related]

  • 3. Do corticotropin releasing factor-1 receptors influence colonic transit and bowel function in women with irritable bowel syndrome?
    Sweetser S, Camilleri M, Linker Nord SJ, Burton DD, Castenada L, Croop R, Tong G, Dockens R, Zinsmeister AR.
    Am J Physiol Gastrointest Liver Physiol; 2009 Jun; 296(6):G1299-306. PubMed ID: 19342506
    [Abstract] [Full Text] [Related]

  • 4. A randomized trial of 5-hydroxytryptamine4-receptor agonist, YKP10811, on colonic transit and bowel function in functional constipation.
    Shin A, Acosta A, Camilleri M, Boldingh A, Burton D, Ryks M, Rhoten D, Zinsmeister AR.
    Clin Gastroenterol Hepatol; 2015 Apr; 13(4):701-8.e1. PubMed ID: 25148765
    [Abstract] [Full Text] [Related]

  • 5. Effect of renzapride on transit in constipation-predominant irritable bowel syndrome.
    Camilleri M, McKinzie S, Fox J, Foxx-Orenstein A, Burton D, Thomforde G, Baxter K, Zinsmeister AR.
    Clin Gastroenterol Hepatol; 2004 Oct; 2(10):895-904. PubMed ID: 15476153
    [Abstract] [Full Text] [Related]

  • 6. Effect of CCK-1 antagonist, dexloxiglumide, in female patients with irritable bowel syndrome: a pharmacodynamic and pharmacogenomic study.
    Cremonini F, Camilleri M, McKinzie S, Carlson P, Camilleri CE, Burton D, Thomforde G, Urrutia R, Zinsmeister AR.
    Am J Gastroenterol; 2005 Mar; 100(3):652-63. PubMed ID: 15743365
    [Abstract] [Full Text] [Related]

  • 7. Effect of tegaserod on colonic transit time in male patients with constipation-predominant irritable bowel syndrome.
    Harish K, Hazeena K, Thomas V, Kumar S, Jose T, Narayanan P.
    J Gastroenterol Hepatol; 2007 Aug; 22(8):1183-9. PubMed ID: 17688659
    [Abstract] [Full Text] [Related]

  • 8. Does co-administration of a non-selective opiate antagonist enhance acceleration of transit by a 5-HT4 agonist in constipation-predominant irritable bowel syndrome? A randomized controlled trial.
    Foxx-Orenstein AE, Camilleri M, Szarka LA, McKinzie S, Burton D, Thomforde G, Baxter K, Zinsmeister AR.
    Neurogastroenterol Motil; 2007 Oct; 19(10):821-30. PubMed ID: 17539894
    [Abstract] [Full Text] [Related]

  • 9. Relamorelin Relieves Constipation and Accelerates Colonic Transit in a Phase 2, Placebo-Controlled, Randomized Trial.
    Acosta A, Camilleri M, Kolar G, Iturrino J, Szarka LA, Boldingh A, Burton D, Ryks M, Rhoten D, Zinsmeister AR, Spence SC, Gottesdiener K, Bouras EP, Vazquez-Roque MI.
    Clin Gastroenterol Hepatol; 2015 Dec; 13(13):2312-9.e1. PubMed ID: 26001337
    [Abstract] [Full Text] [Related]

  • 10. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome.
    Prather CM, Camilleri M, Zinsmeister AR, McKinzie S, Thomforde G.
    Gastroenterology; 2000 Mar; 118(3):463-8. PubMed ID: 10702196
    [Abstract] [Full Text] [Related]

  • 11. Receptor-mediated inhibition of small bowel migrating complex by GLP-1 analog ROSE-010 delivered via pulmonary and systemic routes in the conscious rat.
    Hellström PM, Smithson A, Stowell G, Greene S, Kenny E, Damico C, Leone-Bay A, Baughman R, Grant M, Richardson P.
    Regul Pept; 2012 Nov 10; 179(1-3):71-6. PubMed ID: 22960405
    [Abstract] [Full Text] [Related]

  • 12. Chenodeoxycholate in females with irritable bowel syndrome-constipation: a pharmacodynamic and pharmacogenetic analysis.
    Rao AS, Wong BS, Camilleri M, Odunsi-Shiyanbade ST, McKinzie S, Ryks M, Burton D, Carlson P, Lamsam J, Singh R, Zinsmeister AR.
    Gastroenterology; 2010 Nov 10; 139(5):1549-58, 1558.e1. PubMed ID: 20691689
    [Abstract] [Full Text] [Related]

  • 13. Effects of Velusetrag (TD-5108) on gastrointestinal transit and bowel function in health and pharmacokinetics in health and constipation.
    Manini ML, Camilleri M, Goldberg M, Sweetser S, McKinzie S, Burton D, Wong S, Kitt MM, Li YP, Zinsmeister AR.
    Neurogastroenterol Motil; 2010 Jan 10; 22(1):42-9, e7-8. PubMed ID: 19691492
    [Abstract] [Full Text] [Related]

  • 14. Symptomatic efficacy of beidellitic montmorillonite in irritable bowel syndrome: a randomized, controlled trial.
    Ducrotte P, Dapoigny M, Bonaz B, Siproudhis L.
    Aliment Pharmacol Ther; 2005 Feb 15; 21(4):435-44. PubMed ID: 15709995
    [Abstract] [Full Text] [Related]

  • 15. [A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of tegaserod in Chinese patients with constipation-predominant irritable bowel syndrome].
    Tegaserod Clinical Research Group.
    Zhonghua Nei Ke Za Zhi; 2003 Feb 15; 42(2):88-90. PubMed ID: 12783702
    [Abstract] [Full Text] [Related]

  • 16. Effect of tegaserod on gut transit in male and female subjects.
    Degen L, Petrig C, Studer D, Schroller S, Beglinger C.
    Neurogastroenterol Motil; 2005 Dec 15; 17(6):821-6. PubMed ID: 16336497
    [Abstract] [Full Text] [Related]

  • 17. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety.
    Chey WD, Lembo AJ, Lavins BJ, Shiff SJ, Kurtz CB, Currie MG, MacDougall JE, Jia XD, Shao JZ, Fitch DA, Baird MJ, Schneier HA, Johnston JM.
    Am J Gastroenterol; 2012 Nov 15; 107(11):1702-12. PubMed ID: 22986437
    [Abstract] [Full Text] [Related]

  • 18. A randomised controlled study of the effect of cholinesterase inhibition on colon function in patients with diabetes mellitus and constipation.
    Bharucha AE, Low P, Camilleri M, Veil E, Burton D, Kudva Y, Shah P, Gehrking T, Zinsmeister AR.
    Gut; 2013 May 15; 62(5):708-15. PubMed ID: 22677718
    [Abstract] [Full Text] [Related]

  • 19. Effect of tolterodine on gastrointestinal transit and bowel habits in healthy subjects.
    Bharucha AE, Seide B, Guan Z, Andrews CN, Zinsmeister AR.
    Neurogastroenterol Motil; 2008 Jun 15; 20(6):643-8. PubMed ID: 18312543
    [Abstract] [Full Text] [Related]

  • 20. An exploratory study of the association of adrenergic and serotonergic genotype and gastrointestinal motor functions.
    Grudell AB, Camilleri M, Carlson P, Gorman H, Ryks M, Burton D, Baxter K, Zinsmeister AR.
    Neurogastroenterol Motil; 2008 Mar 15; 20(3):213-9. PubMed ID: 17971028
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 45.